AHH Expands into Urology & Nephrology with AINU Acquisition
Written by Arushi Sharma, Susi
AHH's recent acquisition of AINU marks a strategic expansion into the fields of Urology and Nephrology. This move signifies our commitment to providing comprehensive healthcare solutions to a wider range of patients.
Asia Healthcare Holdings (AHH), a specialized healthcare delivery platform, has acquired a majority stake in the Asian Institute of Nephrology and Urology (AINU) through both primary and secondary investments totaling 600 crore rupees.
This move marks AHH's entry into the Urology and Nephrology sectors, establishing it as the largest single-specialty healthcare delivery platform in India and the Asian subcontinent as a whole.
Vishal Bali, Executive Chairman, Asia Healthcare Holdings said,
“AINU is a distinct single specialty hospital chain in Urology & Nephrology which is built on the foundation of deep clinical expertise and led by clinicians who have decades of experience in this specialty. AINU not only adds a new speciality to the AHH platform but also strengthens our vision of scaling the single specialty healthcare delivery ecosystem in the country. India is amongst the top three nations globally that has the highest incidence Urological disorders, the high incidence of diabetes and hypertension is also accelerating the prevalence chronic kidney disease. We are delighted to partner with AINU and bridge the demand supply gap in the Urology & Nephrology speciality healthcare delivery in the country.”
Dr C Mallikarjun, Chief Consultant Urologist & Managing Director, AINU said, “Indians have a high incidence of kidney stones, and non-cancerous prostate enlargement issues . Increasingly we have observed a rise in the incidence of Urological cancer in the last decade. Cancer of the prostate and bladder are becoming more common. Our team has performed over 1,000 robotic surgeries for urological cancers. We are making Robotic Urology surgery accessible to patients not just in urban India but also in tier 2 cities. Broadly we see a higher incidence of Uro-Oncology, Uro-Gynaecology and Paediatric Urology in the years ahead. We believe AHH has the legacy and is the right partner for the next phase of growth of our enterprise.”